Could Aphria Inc (TSX:APHA) Beat Analyst Revenue Estimates in its Upcoming Earnings Report?

Here’s why investors may witness a massive revenue jump in Aphria Inc’s (TSX:APHA)(NYSE:APHA) upcoming quarterly earnings report on April 15.

edit Cannabis leaves of a plant on a dark background

Image source: Getty Images

Leading Canadian marijuana firm Aphria (TSX:APHA)(NYSE:APHA) is set to release its fiscal third-quarter (Q3 2019) financial results for the period ended February 28 on April 15 before market open. Revenue growth and operating cost management remain the key investor focus right now and there is a strong chance that the company could surpass current analyst top-line projections in the upcoming report.

Public analyst revenue projections for the quarter range between $60 million and $68.92 million, implying a 145% sequential growth from the $24.52 million gross revenue for a previous quarter, or up to 571% year-on-year growth from the $10.27 million sales reported for the same quarter in 2018.

This could be a massive quarterly revenue jump by any standards. How could it come about?

Why the sharp revenue jump?

The company realized a 63% sequential rise in net revenue in a previous quarter, as adult-use cannabis sales boosted sales volumes. However, the previous earnings report only captured roughly a month and a half of recreational sales to month-end November, while the upcoming report covers a full three months of adult-use sales. This could drive substantial cannabis revenue growth.

I expect Canadian segment revenue to come in the range of $30-35 million for the quarter, but there are significant chances for the reading to come in lower.

The forecast above leaves a whole +$30 million in expected revenues unallocated, and the biggest contributor to the company’s revenue growth this time will be the company’s latest European acquisition.

The company completed the acquisition of Germany-based pharmaceuticals distributor CC Pharma GmbH in early January this year. The acquired company has a strong pharmaceuticals distribution footprint across Europe, with access to more than 13,000 pharmacies in Germany — a growing medical cannabis market.

CC Pharma generated €262 million (about $393 million) in revenue for 2018, and that would equate to an average monthly revenue of about $32 million. Considering that the acquisition was completed before January 9, there is a possibility that the new subsidiary contributed close to $60 million in sales during the two months before quarter ended on February 28.

Well set for a revenue beat?

Around $60 million in quarterly revenue could possibly come from CC Pharma if the company chooses gross revenue reporting, and there is a small additional revenue stream from Latin America, too. One would think that the marijuana firm is well set to beat analyst revenue estimates.

However, there were persistent productive capacity challenges during the quarter.

The company was stuck at a functional productive capacity well under 30,000 kilograms per annum throughout the quarter while waiting for new production licences on its extended flagship Aphria One facility, which finally came soon after the quarter had already closed.

Further, January medical and recreational dried marijuana sales were reported weaker than October to December monthly sales, according to Health Canada, and Canadian quarterly sales growth could have been softer for the company, even after new shipments to Shoppers Drug Mart debuted during the quarter and cannabis oil sales picked month on month to January.

Watch the profit margins

The company reported a weaker adjusted gross margin at 47% in the previous report and a negative gross profit for the quarter due to lower product net prices, while production costs soared as productivity declined. I expect production costs to have remained high, as the company grappled with capacity constraints during the quarter.

All-in cost of sales and cash costs to produce marijuana in Canadian operations may have remained elevated.

Canadian operating expenses may remain largely unchanged, but the operating margin may improve with increased revenue generation.

That said, it may be too early to expect a return to positive adjusted EBITDA, as the company may be yet to reach breakeven sales volumes locally.

I will be interested in watching how CC Pharma, which generated a positive 4% EBITDA of €10.5 million ($15.75 million) in 2018, could improve Aphria’s adjusted operating margin for the quarter, but the bottom line will most likely be distorted by realized and unrealized gains from the company’s investment portfolio.

Foolish bottom line

The biggest concern for marijuana investors currently is revenue growth and, to some extent, operating cost management. The company is most likely going to impress on these two fronts in the upcoming earnings release — the first report after the departure of founding CEO Vic Neufeld.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Brian Paradza has no position in any of the stocks mentioned.

More on Cannabis Stocks

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Are Cannabis Stocks Still a Thing in 2023?

The whole question of whether cannabis stocks are still relevant in 2023 is an interesting one. Here's my take on…

Read more »

A cannabis plant grows.
Cannabis Stocks

Why Canopy Growth Stock Fell 72% Last Year

Canopy Growth stock is a beaten-up cannabis giant that is trading at a discount compared to historical multiples. But is…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is SNDL Stock a Buy in January 2023?

SNDL is among the worst-performing cannabis stocks in the last three years. But is SNDL stock a buy right now?

Read more »

a person watches a downward arrow crash through the floor
Cannabis Stocks

Why Tilray Stock Fell Almost 60% in 2022

Tilray is a Canadian cannabis stock that is down 93% from all-time highs. Let's see if TLRY stock is a…

Read more »